PVRV + PVRV and pERIG Favirab® + PVRV and pERIG Favirab®
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Rabies
Conditions
Rabies
Trial Timeline
Jun 29, 2012 → Nov 14, 2018
NCT ID
NCT01622062About PVRV + PVRV and pERIG Favirab® + PVRV and pERIG Favirab®
PVRV + PVRV and pERIG Favirab® + PVRV and pERIG Favirab® is a phase 3 stage product being developed by Sanofi for Rabies. The current trial status is completed. This product is registered under clinical trial identifier NCT01622062. Target conditions include Rabies.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01622062 | Phase 3 | Completed |
Competing Products
20 competing products in Rabies